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High levels of proinflammatory cytokines such as IFN-γ and TNF are associated with tissue lesions in cutaneous leishmaniasis
(CL). We previously demonstrated that Schistosoma mansoni antigens downmodulate the in vitro cytokine response in CL. In
the current study we evaluated whether S. mansoni antigens alter monocyte and T-lymphocyte phenotypes in leishmaniasis.
Peripheral blood mononuclear cells of CL patients were cultured with L. braziliensis antigen in the presence or absence of the
S. mansoni antigens rSm29, rSmTSP-2- and PIII. Cells were stained with fluorochrome conjugated antibodies and analyzed by
flow cytometry. The addition of rSm29 to the cultures decreased the expression of HLA-DR in nonclassical (CD14+CD16++)
monocytes, while the addition of PIII diminished the expression of this molecule in classical (CD14++CD16−) and intermediate
(CD14++CD16+) monocytes. The addition of PIII and rSmTSP-2 resulted in downmodulation of CD80 expression in nonclassical
and CD86 expression in intermediate monocytes, respectively. These two antigens increased the expression of CTLA-4 in CD4+ T
cells and they also expanded the frequency of CD4+CD25highFoxp3+ T cells. Taken together, we show that S. mansoni antigens,
mainly rSmTSP-2 and PIII, are able to decrease the activation status of monocytes and also to upregulate the expression of
modulatory molecules in T lymphocytes.
1. Introduction
American tegumentary leishmaniasis is a disease caused by
parasites of the genus Leishmania. This disease represents
a significative public health problem worldwide with an
incidence of 1.5 million new cases in recent years [1].
Tegumentary leishmaniasis presents with a wide spectrum
of clinical manifestations ranging from localized skin to
widespread mucocutaneous lesions depending on the par-
asite species [2] and the host immune response [3, 4]. T
cell-mediated immunity is crucial to host protection against
Leishmania sp. infection; however skin and mucosal lesions
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occurs due to a deregulated T helper 1 (Th1) cell response
with high production of proinflammatory cytokines such as
IFN-γ and TNF [3, 4].
Experimental studies have shown that Schistosoma man-
soni infection or parasite products, by inducing regulatory
cells and cytokines, are able to prevent some Th1-mediated
autoimmune diseases in mice such as type I diabetes,
experimental autoimmune encephalomyelitis, and psoriasis
[5–7]. Recently, we demonstrated that the recombinant S.
mansoni antigens Sm29 SmTSP-2, and also PIII down-
modulated the production of IFN-γ and TNF in a group
of cutaneous leishmaniasis (CL) patients [8]. In the present
study, these antigens were tested regarding their ability to
alter the monocyte and lymphocyte profiles. Studies have
shown that Sm29 and SmTSP-2 antigens are secreted by the
membrane and/or tegument of the S. mansoni adult worm.
Proteins secreted or localized on the surface of Schistosoma
spp., which are in intimate contact with host tissues, might
be more effective in triggering immunoregulatory processes
[9]. The Sm29 is a membrane-bound glycoprotein located on
the tegument of the adult worm and lung stage schistosomula
[10]. SmTSP-2 is a recombinant protein (tetraspanin) from
S. mansoni tegument. In a mice model, immunization with
SmTSP-2 resulted in a 57% reduction in adult worm burdens
and a 64% reduction in liver egg burdens compared with
control animals [11]. PIII is a multivalent antigen obtained
from S. mansoni adult worms that modulates granuloma size
in mice infected with the parasite [12, 13]. These antigens
have been evaluated by our group regarding their potential to
induce IL-10 production and suppress Th2 response in vitro
in cells of asthmatic individuals [14].
Together with the Th1 immune response, monocytes
and macrophage are key cells in controlling Leishmania sp.
infection. Monocytes have been classifying into different
subpopulations in mice models and also in humans. A
new nomenclature was recently published defining human
monocytes into three subtypes. The major population of
human monocytes (90%) presents high expression of CD14
and lack of expression of CD16 (CD14++CD16−). They are
referred to as classical monocytes. Intermediate monocytes
are those which express CD14 and low CD16 expression
(CD14++CD16+), while the nonclassical monocytes express
CD16 and relatively low CD14 (CD14+CD16++) [15]. In
a study conducted by Wong et al. [16] the characteris-
tics of classical, intermediate and, nonclassical monocytes
were evaluated through the gene expression profiling. They
observed that classical monocytes express genes involved
in angiogenesis, wound healing, and coagulation, being
involved in tissue repair functions in addition to high
expression of proinflammatory genes [16]; intermediate
monocytes highly express MHC class II indicating they
have antigen presenting cell function and T cell stimulatory
properties. Nonclassical monocytes express genes involved in
cytoskeleton rearrangement, whichmay be responsible for its
high motility observed in vivo [17].
A high frequency of CD16+ monocyte subsets have
been demonstrated in Mycobacterium tuberculosis infection
and in viral infections such as hepatitis B (HBV) [18],
hepatitis C (HCV) [19], HIV [20], and Dengue [21]. In
CL patients, the frequency of CD14+CD16+ monocytes was
significantly higher compared to healthy controls and they
were positively correlated with the lesion size [22]. This
subtype of monocytes is considered as antigen presenting
cell [16], which produces cytokines and might be the most
important subtype in activating T cells response.
The activation of T cells requires the antigen recognition
in the MHC context and also signaling given by co-
stimulatory molecules which interact with corresponding
ligands on antigen presenting cells (APC). One of the most
important co-stimulatory molecules on T cells is CD28,
which is constitutively expressed and binds to CD80 and
CD86 on the APC. CD86 is constitutively expressed at low
levels and it is rapidly upregulated after primary antigen
recognition, whereas CD80 exhibits delayed expression
kinetics [23]. Other ligand for CD80 and CD86 is CTLA-4.
The expression of this molecule is rapidly upregulated after
T cell activation and provides a negative signal limiting the
immune response [24–26]. In vitro study has shown that the
addition of CTLA-4-Ig to block CD28-B7 interaction in CL
patients PBMC cultures stimulated with Leishmania antigen
led to a downmodulation of IFN-γ and TNF secretion [27].
Other similar study showed that blocking the co-stimulatory
molecules CD80 and CD86 in human macrophages from
Leishmania-naive donors infected with L. major resulted in
a significant reduction in IFN-γ, IL-5, and IL-12 production
[28].
In this study we evaluated whether S. mansoni antigens
alter the expression of CD80 and CD86 on monocytes of CL
patients and also the expression of CTLA-4 in T lymphocytes.
Additionally, we accessed the frequency of regulatory T cells
induced by S. mansoni antigens when they were added to the
cell cultures stimulated with Leishmania antigens.
The CD4+CD25+ regulatory T cells have been extensively
studied due to their critical function in maintaining self-
tolerance. These cells can express both low and high CD25
levels in mice models; however, only the CD4+CD25high
population exhibits a strong regulatory function in humans.
These CD4+CD25high T cells also express FOXP3, a molecule
associated with regulatory functions [29]. This T cell subset
in humans comprises ∼1.5–3% of circulating CD4+ T cells.
They inhibit proliferation and cytokine secretion induced
by TCR cross-linking of CD4+CD25− responder T cells in
a contact-dependent manner [30] and completely abrogate
IL-2-dependent proliferation of NK cells [31]. Moreover,
regulatory T cells are able to downregulate the intensity
and duration of both Th1 and Th2 immune responses in
infectious diseases limiting damage to self-tissue [32, 33].
Our hypothesis in the present study is that the pathology
of cutaneous leishmaniasis results from monocyte and T
cell hypersensitivity due to impaired regulatory mechanisms.
In this context, the use of S. mansoni antigens which
induce regulatory cells and molecules would prevent the
inflammatory process. To test this hypothesis we evaluated
whether the addition of S. mansoni antigens to cell cultures
of leishmaniasis patients would modify the phenotype and
activation status of monocytes and lymphocytes. Specifically,
we evaluated the expression of HLA-DR, CD80, and CD86
on classical, intermediate, and nonclassical monocytes and
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CD28, CTLA-4, CD25, and Foxp3 in T lymphocytes from
CL patients in response to the soluble Leishmania braziliensis
antigen (SLA) in the presence or absence of the S. mansoni
antigens rSm29, rSmTSP-2, and PIII.
2. Materials and Methods
2.1. Patients and the Endemic Area. The study included
the first 30 cutaneous leishmaniasis patients living in the
endemic area of tegumentary leishmaniasis, Corte de Pedra,
Bahia, Brazil, who attended the local Health Post fromMarch
2010 to March 2012 and agreed in participate. Corte de
Pedra is located in the southeast region of the State of Bahia,
Brazil which is well known for its high rate of L. braziliensis
transmission.
The diagnostic of cutaneous leishmaniasis was made
considering a clinical picture characteristic of CL, parasite
isolation or a positive delayed-type hypersensitivity (DTH)
response to Leishmania antigen, and a histological feature of
CL.
The inclusion criteria to this study were patients with
5 to 60 years of age diagnosis of CL with the presence of
active skin lesions. The exclusion criteria were pregnancy,
chronic diseases such as diabetes and asthma, and also HIV
and HTLV-1 infection.
Immunological analyses were performed prior to the
specific therapy to leishmaniasis for all patients. There were
not enough cells to perform the whole experiment every time
since they require a larger number of cells more than what
could be obtained from some patients.
The frequency of helminth infection in the leishmaniasis
endemic area of Corte de Pedra is 88.3% and S. mansoni
infection presents in 16.7% of cutaneous leishmaniasis
patients.
The Ethical Committee of the Maternidade Clime´rio de
Oliveira, Federal University of Bahia approved the present
study, and an informed consent was obtained from all
participants or their legal guardians.
2.2. Antigen Preparation. The soluble Leishmania antigen
used in this study was obtained from a Leishmania lysate
(crude antigen). It was prepared from a L. braziliensis strain
(MHOM/BR/2001) as previously described [34].
The S. mansoni antigens used in this study included
Sm29, a Schistosoma mansoni recombinant protein [10];
SmTSP-2, a recombinant protein (tetraspanin) from S.
mansoni tegument [11]; a fraction of S. mansoni soluble adult
worm antigen (SWAP) obtained by anionic chromatography
(FPLC), called PIII. The Sm29 was cloned in E. coli and
tested for lipopolysaccharide (LPS) contamination using a
commercially available LAL Chromogenic Kit (CAMBREX).
The levels of LPS in Sm29 were below 0.25 ng/mL. However
in order to neutralize potential effects of LPS presented in
low levels in the S. mansoni recombinant antigen, Polymyxin
B was added to cell cultures every 12 hours according
to the established protocol [35]. The SmTSP-2 used in
this study was produced in Pichia pastoris fermentation
cultures and it has been kindly provided by Dr. Alex Loukas
[11, 36]. The proteins rSm29 and PIII were provided by the
Institute of Biological Science, Department of Biochemistry
and Immunology, UFMG, Brazil.
2.3. Cell Culture and Intracellular and Surface Staining.
Intracellular and surface molecules were evaluated by flow
cytometry (FACSort, BD Biosciences, San Jose, CA). In
order to perform the intracellular staining, peripheral blood
mononuclear cells (PBMC, 3 × 105) obtained through the
Ficoll-Hypaque gradient were cultured in vitro with SLA
(5 μg/mL) in the presence or absence of the recombinant
S. mansoni antigens Sm29, SmTSP-2, and PIII (5 μg/mL)
for 20 h, 37◦C, and 5% of CO2. During the last 4 h of
culture, Brefeldin A (10 μg/mL; Sigma, St. Louis, MO),
which impairs protein secretion by the Golgi complex, was
added to the cultures. Afterwards, the cells were washed
in PBS and fixed in 4% formaldehyde for 20min at room
temperature. Specific staining was performed with cychrome
(CY)-labeled antibody conjugated with anti-CTLA-4 mAbs
in saponin buffer (PBS, supplemented with 0.5% BSA and
0.5% saponin) and phycoerythrin (PE)-labeled antibody
conjugated with anti-Foxp3 in Foxp3 staining buffer set
(eBioscience). For double or triple staining, mAbs to human
CD4, CD8, and/or CD25 conjugated with FITC or CY were
used.
The evaluation of co-stimulatory molecule expression
was performed in PBMCs stimulated for 60 h with the
same antigens aforementioned. Cells were incubated with
fluorescein isothiocyanate (FITC)-, PE-, or CY-labeled anti-
body solutions for 20min at 4◦C in a volume of 20 μL in
PBS. After staining, preparations were washed with 0.1%
sodium azide PBS, fixed with 200 μL of 4% formaldehyde
in PBS and kept at 4◦C. The antibodies used for the
staining were immunoglobulin isotype controls-FITC, PE
and CY, anti-CD4-FITC, anti-CD8-FITC, anti-CD25-FITC,
anti-CD14-FITC, CD16-CY, anti-CD4-CY and anti-CD8-
CY, anti-CD80-PE, anti-CD86-PE, anti-HLA-DR-PE, anti-
CD28-PE (all from BD Biosciences Pharmingen). A total
of 50,000 and 100,000 events were acquired for surface and
intracellular experiments, respectively.
2.4. Analysis of FACS Data. The frequency of positive cells
was analyzed by flow cytometry using the program flowjo
in two regions. The lymphocyte region was determined
using granularity (SSC) × size (FSC) plot. Monocytes were
selected based on their granularity and expression of CD14
and CD16. Limits for the quadrant markers were always
set based on negative populations and isotype controls. A
representative density graph of one experiment showing
lymphocyte and monocyte regions is shown in Figures 1(a)
and 1(b), respectively.
2.5. Statistical Analyses. Statistical analyses were performed
using the software GraphPad Prism (GraphPad Software, San
Diego, CA). The frequency of positive cells was expressed
as percentages and the intensity of expression as mean
intensity fluorescence (MFI). The differences between means
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Figure 1: Strategy for T cell and monocytes evaluation by flow cytometry. The cell populations were defined by nonspecific fluorescence
from the forward (FSC) and side scatter (SSC) as parameters of cell size and granularity, respectively. Lymphocytes region was determined
using SSC × FSC plot (G1) and monocytes region (G2) were selected based on their granularity and expression of CD14 (a). (b) represents
the strategy for monocytes subsets classification through the expression of CD14 and CD16. Representative graph of one experiment.
Table 1: Demographic characteristics of the cutaneous leishmania-
sis patients included in the study.
Characteristics (n = 30) Values
Age, mean± SD, years 29.1± 11.8
Sex, female/male 13/17
N◦ of lesion
1, no. (%) 24 (80.0)
≥2, no. (%) 06 (20.0)
Size of lesion, median mm2 (IQR) 130 (66.5–342)
IQR: interquartile range; SD: standard deviation.
were assessed using Wilcoxon matched pairs test. Statistical
significance was established at the 95% confidence interval.
3. Results
A total of 30 patients with cutaneous leishmaniasis were
enrolled in this study, 17 were male and 13 were female,
with a mean age of 29.1 ± 11.8 years (range 6–48 years).
The majority of patients presented with a single lesion (80%)
and the median lesions size was 130mm2 (IQR, 66.5–342;
Table 1).
3.1. The Effect of the Addition of S. mansoni Antigens onMono-
cyte Phenotype and Expression of Co-Stimulatory Molecules.
We evaluated the frequency of different monocyte subsets
(classical, intermediate, and nonclassical) and also the
expression of co-stimulatory molecules in these monocytes
after in vitro stimulation with SLA in the presence or
absence of S. mansoni antigens. The addition of the antigens
rSm29 and PIII to the cultures expanded the frequency of
nonclassical (CD14+CD16++) (mean ± SEM = 7.4± 1.2%
and 8.1± 1.9%, resp.) compared to cultures stimulated with
SLA alone (5.7 ± 0.9%; P < 0.05. Figure 2(A)). We also
observed that the frequency of classical monocytes was
higher in cultures without S. mansoni antigens (Figure 2(A)).
Moreover, in the presence of PIII there was a reduction in
the expression of HLA-DR in classical (CD14++CD16−) and
intermediate (CD14++CD16+) monocytes (496±72MFI and
544± 78.6 MFI, resp.) compared to cultures stimulated with
SLA alone (611 ± 91 MFI and 771 ± 128 MFI, respectively;
P < 0.05. Figure 2(B)). There was also a reduction in
HLA-DR expression on CD14+CD16++ monocytes in the
presence of rSm29 (547 ± 140.5 MFI) in comparison to
SLA alone (718 ± 188.4 MFI; P < 0.05. Figure 2(B)).
Additionally, the expression of HLA-DR was higher in
classical and intermediate monocytes in the presence of SLA
or SLA plus S. mansoni antigens compared to nonstimulated
cultures.
The expression of CD80 was also reduced in nonclassical
monocytes compared to cultures stimulated with SLA. The
addition of PIII to the cultures also resulted in reduced
expression of the co-stimulatory molecule CD80 on
nonclassical monocytes (61.2 ± 19.5 MFI) compared to cul-
tures without S. mansoni antigens (82.3±23.3MFI; P < 0.05.
Figure 2(C)). Also a decrease in the expression of CD86 on
intermediate monocytes from 562 ± 149.7 MFI to 447.8 ±
112.5 MFI was observed when rSmTSP-2 was added to the
cultures (P < 0.05; Figure 2(D)). There was no significant
difference in the levels of CD86 expression on monocytes in
culture stimulated with SLA after the addition of rSm29 and
PIII (Figure 2(D)).
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Figure 2: Subsets of monocytes and co-stimulatory molecules expression in monocytes of CL patients (n = 18) stimulated in vitro with
SLA in the presence or absence of S. mansoni antigens rSm29 and rSmTSP-2 or with a fraction of S. mansoni soluble adult worm antigen
(SWAP) PIII. Frequency of classical (CD14++CD16−), intermediate (CD14++CD16+) and nonclassical (CD14+CD16++), monocytes (A),
and expression of HLA-DR, CD80, and CD86 in classical, intermediate and nonclassical monocytes of cutaneous leishmaniasis patients (B–
D). Cells were stained for surface expression of CD14, CD16, HLA-DR, CD80, and CD86 using flow cytometry. aP < 0.05 cultures without
stimulation (WS) versus SLA + S. mansoni antigens; bP < 0.05 SLA versus SLA + S. mansoni antigens (Wilcoxon matched pairs test).
3.2. The Effect of the Addition of S. mansoni Antigens on T
Cell Phenotype and Expression of Co-Stimulatory Molecules.
PBMC of CL patients were incubated with SLA in the pres-
ence or absence of S. mansoni antigens and the phenotype of
T cells were evaluated. The addition of rSm29 antigen to the
cultures increased the frequency of CD4+ T cells (mean ±
SEM = 40.8 ± 2.8%) in comparison to cultures with SLA
alone (34.8 ± 2.8%, P < 0.05; Figure 3(A)). There was no
significant difference in the frequency of CD4+ T cells after
the addition of rSmTSP-2 or PIII antigens to the cultures
(37.8 ± 2.7% and 35.8 ± 2.6%, resp.) compared to SLA
alone (34.8 ± 2.8%; Figure 3(A)). Likewise, there was no
significant variation in the frequency of CD8+ T cells by the
presence of rSm29, rSmTSP-2, and PIII antigens (5.9±1.2%,
4.6±0.8%, and 6.2±1.1%, resp.) to the cultures in relation to
the cultures stimulated with SLAwithout S. mansoni antigens
(5.7± 1.2%; Figure 3(A)). The frequency of CD4+ T cells was
diminished by the presence of SLA and SLA plus rSmTSP-2
or PIII, while the frequency of CD8+ T cells was higher in
the presence of SLA and SLA plus S. mansoni antigens
compared to nonstimulated cultures (Figure 3(A)).
We also evaluated the expression of CD28+ on lympho-
cytes in cultures stimulated with SLA with or without the
addition of S. mansoni antigens. The expression of CD28+ on
CD8+ T cells was higher in cultures stimulated with rSm29
(91 ± 14 MFI, resp.) compared with SLA alone (84 ± 14
MFI; P < 0.05. Figure 3(B)). The addition of rSmTSP-2 and
PIII antigens to the cultures did not alter significantly the
expression of CD28 onCD4+ and CD8+ T cells (Figure 3(B)).
Regarding the expression of CTLA-4, rSmTSP-2 and PIII
antigens were able to increase the expression of this molecule
in CD4+ T cells (58±5 MFI and 53±4.6 MFI, resp.) in com-
parison with SLA alone (49.6±4 MFI, respectively; P < 0.05.
Figure 3(C)). The expression of CTLA-4 was also higher
in CD4+ T cells and CD8+ T cells in cultures stimulated
with SLA plus rSmTSP-2 or PIII compared to nonstimulated
cultures (Figure 3(C)). Moreover, the addition of rSmTSP-2
and PIII antigens to the cultures expanded the frequency of
6 Journal of Parasitology Research
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Figure 3: Phenotype of T cells and co-stimulatory molecules expression on T lymphocytes of CL patients (n = 17) stimulated in vitro
with SLA in the presence or absence of S. mansoni antigens rSm29, rSmTSP-2 or with a fraction of S. mansoni soluble adult worm antigen
(SWAP) PIII. Frequency of CD4+ and CD8+ T cells (A), expression of CD28 and CTLA-4 in CD4+ and CD8+ T cells (B and C, resp.) and the
frequency of CD4+CD25highFoxp3+ T cells (n = 13) (D). Cells were stained for surface expression of CD4, CD8, CD25 and CD28, while the
expression of CTLA-4 and Foxp3 were evaluated intracellularly using flow cytometry. aP < 0.05 cultures without stimulation (WS) versus
SLA + S. mansoni antigens; bP < 0.05 SLA versus SLA + S. mansoni antigens (Wilcoxon matched pairs test).
CD4+CD25highFoxp3+ T cells (10 ± 2.4% and 10.3 ± 1.9%,
resp.) compared to cultures with SLA in the absence of
S. mansoni antigens (8.1 ± 1.8%; P < 0.05. Figure 3(D)).
The frequency of CD4+CD25highFoxp3+ T cells was also
higher in cultures stimulated with SLA plus PIII compared
to nonstimulated cultures (Figure 3(D)).
4. Discussion
The Th1 immune response associated with macrophage acti-
vation and killing of Leishmania sp. is paradoxically related to
the development of cutaneous and mucosal leishmaniasis. In
an attempt to control parasite growth, activatedmacrophages
release high levels of proinflammatory cytokines and nitro-
gen and oxygen reactive intermediates, leading to a tissue
lesion.
A balance between the proinflammatory response char-
acterized by the production of IFN-γ and TNF, and the
regulatory response with the production of IL-10 has
been observed in individuals exposed to the Leishmania
braziliensis in endemic areas of leishmaniasis in Brazil.
Those individuals do not develop the disease and they
are designated as “subclinical” subjects [37]. The balanced
immune response described in these individuals may be the
key to achieving a harmless host-parasite relationship.
There are other evidences that IL-10 is capable of
downmodulating the inflammatory response associated with
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human tegumentary leishmaniasis [4, 38–40]. However,
mononuclear cells of mucosal leishmaniasis (ML) patients
have a decreased ability to produce this cytokine and to
respond to IL-10 after in vitro restimulation with L. brazilien-
sis antigen [3].
Recently it has been shown that during chronic Schis-
tosoma mansoni infection, cells from the innate immune
response, such as monocytes and regulatory T cells produce
high levels of IL-10 [24, 41–43]. Our group has performed
studies in an attempt to identify S. mansoni antigens with
regulatory properties that enable them to downregulate
the inflammatory process associated with certain immune-
mediated diseases. For instance, we have shown that the S.
mansoni antigens rSm29, rSmTSP-2, and PIII induce IL-10
and IL-5 production by PBMC of cutaneous leishmaniasis
patients and that they are able to control the in vitro
inflammatory response in a group of patients, independent
of the clinical features, such as number and size of lesions
[8]. In this current study we extended the assessment
of the potential of the antigens rSm29, rSmTSP-2, and
PIII in modifying the immune response during cutaneous
leishmaniasis. Specifically, we evaluated the impact of the
addition of these antigens to the cell culture stimulated with
Leishmania antigens on monocyte and lymphocyte profile
and activation status.
CD4+ T lymphocytes and monocytes are key cells in the
protection against leishmaniasis; however they have been
associated to the inflammatory process and tissue lesion in
the cutaneous form of disease [20, 44–46]. In leishmaniasis
and also in some others diseases the role of different subsets
of monocytes in the pathology has been described [47].
For more than two decades, monocytes have been classified
into classical (CD14+CD16−) and inflammatory, those which
express the molecule CD16 and produce high levels of TNF-
α [48]. The frequency of CD14+CD16+ in CL patients was
found to be significantly higher compared to healthy controls
and they were positively correlated with the lesion size [22].
Recently, a new nomenclature has been used to clas-
sify human blood monocytes into three subsets: classi-
cal (CD14++CD16−), intermediate (CD14++CD16+), and
nonclassical (CD14+CD16++) [15]. The classical monocytes
account for about 85% of the total monocytes and are
characterized by the expression of IL-13Rα1, IL-10, and
RANTES and by the expression of genes associated with anti-
apoptosis and wound healing properties. The intermediate
monocytes represent 5% of monocytes, express high levels
of HLA-DR and are associated with antigen processing and
presentation to T cell and T cell activation. Nonclassical
subset are characterized by a low expression of CD14 and
high expression of CD16 (CD14+CD16++). They represent
10% of human monocytes and studies have shown that they
express genes associated with cytoskeletal rearrangement
which account for their highly mobility and for the patrolling
behavior in vivo [16, 47].
Since the roles of the different monocyte subsets in
cutaneous leishmaniasis remain unclear, we decided to
evaluate not only their frequency in leishmaniasis patients,
but also whether the addition of S. mansoni antigens would
alter the profile of these cells in an in vitro study.
The addition of the antigens rSm29 and PIII to the
PBMC cultures stimulated with SLA increased the frequency
of nonclassical monocytes. This was not expected as a cell
with high mobility and migratory capacity [16, 47], they
may contribute to Leishmania metastasis and consequent
development of more severe forms of the disease, such as the
mucosal and disseminated forms.
We found, however, that the S. mansoni antigens used
in this study, particularly PIII, diminished the expression
of HLA-DR as well as the expression of the co-stimulatory
molecules B7.1 and B7.2 on different monocyte subsets.
A downmodulation of monocyte activation is desirable in
leishmaniasis and may result in a reduced inflammatory
process.
In this study, we also evaluated the expression of co-
stimulatory molecules in T cells. We observed a significant
increase in the frequency of CD4+ T cells by the presence of
the rSm29 antigen in the cultures. The addition of rSmTSP-2
and PIII antigens to the cultures stimulated with SLA
increased the expression of CTLA-4 in CD4+ T cells and also
expanded the frequency of CD4+CD25highFoxp3+ T cells. We
previously showed that S. mansoni infection expands CD4+
T cell population of the regulatory profile in S. mansoni-
infected asthmatic individuals [24]. In such allergic disease,
S. mansoni antigens downmodulate the Th2 exacerbated
inflammatory response in vitro by inducing the production
of IL-10 and the expression of the regulatory molecules,
CTLA-4 in T lymphocytes [9, 24, 43]. In a murine model of
ovalbumin-induced asthma, inhibition of lung inflammatory
process, by S. mansoni eggs or by the S. mansoni antigens,
Sm22.6, PIII, and rSm29 were associated with an increase in
the number of CD4+CD25+Foxp3+ T cells and high levels of
IL-10 production [49, 50].
T cell-mediated immunity is fundamental to host pro-
tection against Leishmania sp. and the activation of T cells
depends upon signals from the interaction between the co-
stimulatory molecules CD28 to its ligands B7.1 and B7.2
on antigen presenting cells (APCs) [23]. We evaluated the
expression of CD28 on lymphocytes in cultures stimulated
with SLA with or without the addition of S. mansoni
antigens and found that the expression of this molecule
on CD8+ T cells was higher in cultures stimulated with
rSm29 compared with SLA alone. These results suggest that
the CD8+ T cells became more activated in the presence
of rSm29. There was, however, an increased expression of
CTLA-4 in CD4+ T cells, a molecule which is expressed
to inhibit the T cell activation when rSmTSP-2 and PIII
were added to the cultures. In vitro study has shown that
the addition of CTLA-4-Ig to block CD28-B7 interaction
in CL patients, PBMC cultures stimulated with Leishmania
antigen led to a downmodulation of IFN-γ, IL-10, and TNF
secretion [27]. Our findings suggest that the CD4+ T cells
were downmodulated by the presence of the rSmTSP-2 and
PIII. These antigens were also able to increase the frequency
of the CD4+CD25highFoxp3+ regulatory T cells.
In a survey performed by O’Neal et al. [51], the preva-
lence of S. mansoni infection in cutaneous leishmaniasis
patients from the endemic area of Corte de Pedra, Bahia,
Brazil was 16.7% [51]. The authors also showed that
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coinfected individuals tended to have small lesion size,
however in the univariated model, the presence of helminth
coinfection was associated with delayed lesion healing. When
they evaluated infection with S. mansoni and Strongyloides
stercoralis there was no difference in lesion healing compared
to patients infected with geohelminths such as Ascaris
lumbricoides, Ancylostoma duodenale, and Trichuris trichiura.
Studies conducted by the same group in the endemic
area of leishmaniasis in Brazil demonstrated that the use of
immunomodulatory agents such as granulocyte/macrophage
colony stimulating factor (GM-CSF) and pentoxifylline, an
inhibitor of TNF production, can lead to faster healing time
and higher cure rate in cutaneous leishmaniasis [52–55]. It
has also been reported that intralesional injections of GM-
CSF reduce healing time of CL ulcers by 50%. Moreover,
Santos et al. [53] showed that GM-CSF applied locally in
low doses as an adjuvant to pentavalent antimonial therapy,
significantly decreases the healing time of CL ulcers, reducing
the dose of antimony administered and/or the duration
of antimonial therapy. These studies indicate that down-
modulation of the inflammatory response in CL patients is
associated with lesion cure and give support to the idea that
inhibition of the strong inflammatory response early after
Leishmania infection could avert tissue damage.
In this context, the data presented herein suggest that S.
mansoni antigens are capable of downregulating monocyte
and T lymphocyte response to the Leishmania antigen in
vitro, possibly through mechanisms that involve negative
signaling by CTLA-4 and the action of regulatory T cells.
This knowledge could contribute to the development of
future strategies to prevent and treat cutaneous and mucosal
leishmaniasis.
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